drugset / Trial / NCT02278328
MEG Study of Acute STX209 Effects in ASD
Phase 0
Completed
25 enrolled
Timothy Roberts
Clinical Research Associates, LLC · collabSimons Foundation · collab
RandomizedCrossoverOpen-labelBasic science
Summary
This is a single-site, randomized, acute dose-response study to determine whether STX209 produces a dose-dependent significant change in MEG target parameters compared to baseline as well as compared to placebo treatment.
Timeline
- Start
- 2016-02
- Primary completion
- 2018-07-30
- Completion
- 2019-09-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Arbaclofen | Small molecule | 15 mg | Oral |
| Subject | Arbaclofen | Small molecule | 30 mg | Oral |